ProCE Banner Activity

JAVELIN Bladder 100: Long-term Follow-up of Avelumab Maintenance for Advanced Urothelial Cancer by First-line Chemotherapy Regimen

Capsule Summary
Conference Coverage

With >3 years of follow-up, avelumab maintenance therapy continues to show survival benefit vs best supportive care for patients with advanced urothelial carcinoma without disease progression regardless of first-line chemotherapy regimen received.

Released: February 27, 2023

Expiration: February 26, 2024

Begin Activity


Provided by

ProCE Banner


Bayer HealthCare Pharmaceuticals Inc

Exelixis, Inc.

Gilead Sciences, Inc.

Pfizer, Inc.